GALMED PHARMACEUTICALS LTD (GLMD)
IL0011313900 - Common Stock
Taking everything into account, GLMD scores 3 out of 10 in our fundamental rating. GLMD was compared to 568 industry peers in the Biotechnology industry. GLMD has a great financial health rating, but its profitability evaluates not so good. GLMD is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year GLMD has reported negative net income.
In the past year GLMD has reported a negative cash flow from operations.
In the past 5 years GLMD always reported negative net income.
In the past 5 years GLMD always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -30.19%, GLMD is doing good in the industry, outperforming 67.43% of the companies in the same industry.
The Return On Equity of GLMD (-34.30%) is better than 76.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.19% | ||
| ROE | -34.3% | ||
| ROIC | N/A |
ROA(3y)-79.39%
ROA(5y)-63.92%
ROE(3y)-96.47%
ROE(5y)-76.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GLMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, GLMD has less shares outstanding
The number of shares outstanding for GLMD has been reduced compared to 5 years ago.
There is no outstanding debt for GLMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
GLMD has an Altman-Z score of -12.28. This is a bad value and indicates that GLMD is not financially healthy and even has some risk of bankruptcy.
GLMD has a Altman-Z score of -12.28. This is in the lower half of the industry: GLMD underperforms 78.41% of its industry peers.
There is no outstanding debt for GLMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.28 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 7.03 indicates that GLMD has no problem at all paying its short term obligations.
GLMD has a better Current ratio (7.03) than 67.79% of its industry peers.
A Quick Ratio of 7.03 indicates that GLMD has no problem at all paying its short term obligations.
The Quick ratio of GLMD (7.03) is better than 67.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.03 | ||
| Quick Ratio | 7.03 |
3. Growth
3.1 Past
GLMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.95%, which is quite impressive.
EPS 1Y (TTM)68.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-878.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, GLMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.32% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.64%
EPS Next 2Y40.47%
EPS Next 3Y25.44%
EPS Next 5Y14.32%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GLMD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLMD. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
GLMD's earnings are expected to grow with 25.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.47%
EPS Next 3Y25.44%
5. Dividend
5.1 Amount
GLMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GALMED PHARMACEUTICALS LTD
NASDAQ:GLMD (12/20/2024, 8:14:55 PM)
3.05
-0.02 (-0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.32%
Inst Owner Change-81.03%
Ins Owners1.29%
Ins Owner ChangeN/A
Market Cap4.61M
Analysts82.86
Price Target12.24 (301.31%)
Short Float %1.53%
Short Ratio0.26
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1100%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.25 | ||
| P/tB | 0.25 | ||
| EV/EBITDA | N/A |
EPS(TTM)-39.12
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-3.18
FCFYN/A
OCF(TTM)-3.18
OCFYN/A
SpS0
BVpS12.21
TBVpS12.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.19% | ||
| ROE | -34.3% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-79.39%
ROA(5y)-63.92%
ROE(3y)-96.47%
ROE(5y)-76.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.03 | ||
| Quick Ratio | 7.03 | ||
| Altman-Z | -12.28 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)8.33%
Cap/Depr(5y)30%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-878.46%
EPS Next Y96.64%
EPS Next 2Y40.47%
EPS Next 3Y25.44%
EPS Next 5Y14.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.6%
OCF growth 3YN/A
OCF growth 5YN/A